

NUCLEAR MEDICINE

Abstract

Nuclear medicine is a medical specialty which uses radiopharmaceuticals for diagnosis and treatment. Radiopharmaceuticals are targeted compounds that have radionuclide for obtaining the images of the location of diagnosis and treatment. Using tools like gamma cameras, it is possible to objectively detect, measure and picture the ionizing radiations that come along with the radioactivity that has been injected. Nuclear medicine is used in diagnosis and therapy and has grown from simple *in vitro* test to advanced methods for imaging organ function. These include gamma cameras, SPECT and PET scanners, and single-photon emission computed tomography (SPECT) scanners. This chapter is focused on the history, diagnostic and clinical applications of nuclear medicine and design of radiopharmaceuticals.

Keywords: Nuclear Medicine, Radiopharmaceuticals, PET, SPECT, Radionuclide

Authors

Kavita Sangwan

Department of Pharmacy
Panipat Institute of Engineering and
Technology (PIET) Samalkha
Panipat, Haryana, India.

Suman Khurana

Department of Pharmacy
Panipat Institute of Engineering and
Technology (PIET) Samalkha
Panipat, Haryana, India.

Amity Institute of Pharmacy, Amity
University Haryana Amity Education Valley
Manesar, Gurugram, Haryana. India.

Arun Mittal

Amity Institute of Pharmacy
Amity University Haryana Amity Education
Valley Manesar, Gurugram
Haryana, India.

Parveen Kumar Goyal

Department of Pharmacy
Panipat Institute of Engineering and
Technology (PIET) Samalkha
Panipat, Haryana, India.

Rupali Sharma


Amity Institute of Pharmacy
Amity University Haryana Amity Education
Valley Manesar, Gurugram
Haryana, India.

I. INTRODUCTION

Nuclear medicine uses radiopharmaceuticals for diagnosing and treating the diseases (1,2). Radiopharmaceuticals are targeting compounds such as biologicals, chemicals or particles that are radiolabeled (3). Radiopharmaceuticals should be prepared and used in a safe and knowledgeable manner due to risk of ionizing radiations emitted from them (4). In order to design effective nuclear medicine for therapeutic and diagnostic imaging, it is essential to understand the ways and mechanism of interactions of the radioactive elements with different entities such as medicinal compounds, and biologicals especially (5). Nuclear medicine is generally administered via oral, nasal and intravenous route. With the help of gamma cameras, it is possible to detect, measure and image the ionizing radiations which are emitted due to decay of administered radiopharmaceuticals. Single photon emission computed tomography (SPECT), positron emission tomography (PET), PET-CT, micro-PET (with ultra-high resolution), and micro computerized axial tomography are illustrations of nuclear medicine techniques. These techniques are used to investigate the origins of biochemical dysfunctions as early illness indicators, their relationships to a variety of disease states, such as cancer, cardiovascular disease, and mental disorders (6,7,8). Nuclear Medicine imaging offers a number of important advantages in clinical practice, as well as in preclinical and clinical research such as it is non-invasive, quantitative or semiquantitative and having high detection sensitivity as compared to other imaging procedures like computer tomography and magnetic resonance imaging (9). The pictures produced by positron emission tomography (PET) are entirely quantitative and parameterizable according to the quantity of radioactivity present (for instance, in units of MBq/cm³)(10). The type of radiation employed determines the diagnostic and therapeutic applications such as Technetium-99m is the most often utilized agent for gamma emitters in diagnostic procedures and iodine-131 for beta emitters for treatments. (11). For illnesses in oncology, cardiology, neurology, infectious and inflammatory diseases, nuclear medicine has diagnostic, prognostic, predictive, and intermediate endpoint biomarkers (12). This chapter mainly focuses on the history, design of radiopharmaceuticals, diagnostic and clinical applications of nuclear medicine.

II. HISTORY

1. Artificial radioactivity: By subjecting stable nuclides to alpha particle radiation in 1934, René and Frédéric Joliot-Curie generated radioactive elements, continuing the work of Pierre and Marie Curie. More specifically, the Joliot-Curies used alpha particles to attack a variety of elements, such as H, He, Li, B, Be, C, N, O, F, Na, Al, Ca, Mg, Ni, and Ag. Aluminum (Z = 13) was blasted by Polonium's alpha particles decay, resulting in the production of (Z = 15) Radioactive phosphorus and a neutron.



They were able to prove that In fact, they had formed artificially introducing a new element by condensing the radioisotope nitrogen-13, which emits positrons into a different vessel after a similar reaction with boron, which released radiation within a t_{1/2} of ten minutes. But they quickly managed to replicate and validate their finding of the creation of artificial radioactivity (13). The Nobel Prize was given to Irène and Frédéric

Joliot-Curie in 1935 for contribution to production of new radioactive elements (14). Lawrence was using the cyclotron to produce fake radioactivity as well, but he was oblivious to these residual emissions because the lab's Geiger counter was controlled by the same switch as the cyclotron. In 1938 at Berkeley, Emilio Segre and Glenn Seaborg and John Livingood made the discoveries of technetium-99m and iodine-131 owing to the efforts of Lawrence's crew and the early 1930s with the Joliot-Curies. Lawrence earned the Nobel Prize in 1939 for developing and creating the cyclotron and for the investigations he conducted with it, particularly in relation to synthetic radioactive elements" as a result of his diligent work, and it also opened the way for the radionuclide production for SPECT and PET using cyclotron (15). The "father of nuclear medicine," George de Hevesy, initially proposed the radiotracer concept, which supports using radionuclides to examine the stable atoms and molecules' behavior (16). In the first radiotracer experiment on animals, bismuth-210 was used to track the flow of Bi-containing antisyphilitic drugs in rabbits (17, 6). De Hevesy and a colleague used the isotopic dilution technique for the first time in clinical sciences to calculate their bodily water content, which was 43 liters with a 50% turnover every nine days (18). Of course, these were the initial subjects, consuming progressively larger aliquots of water that had been tracer-injected with deuterium. One of the most significant investigations revealed that the skeleton could absorb and release phosphorus, demonstrating for the first time that the bone is an active organ like any other(19).

- 2. Iodine radionuclides:** Only a few years after iodine's discovery in seaweed in 1811, the effects of iodine on the thyroid were first researched. Amazingly, it took only 8 years for iodine to be employed as a goiter treatment (20). Saul Hertz, a member (and eventually director) of the MGH Thyroid Clinic, questioned whether iodine could be turned radioactive during a colloquium at Harvard Medical School in 1936. Then-MGH President Karl Compton promised to look into it. The outcome was a cooperative initiative between the Massachusetts Institute of Technology and the Massachusetts General Hospital that was designed to produce iodine -128 ($t_{1/2} = 25$ min) utilizing a neutron source and research its absorption in rabbits (21). They announced their findings in 1938 after using deuterons from the Berkeley cyclotron to bombard tellurium -128 and produce Iodine-130 ($t_{1/2}$: 12 hours) and Iodine-131 ($t_{1/2}$: 8 days)(22). Iodine -131 studies in the future made it possible to trace the radionuclide in living things for extended periods of time (23). They discovered that the therapy of metastases required thyroid ablation, which lessened the thyroid's competition for iodine uptake(24, 25). These groundbreaking trials transformed thyroid carcinoma from a terminal illness to one with an approximate 85% overall survival rate (26).
- 3. Carbon radionuclides:** In the late 1930s, carbon-11 (C^{11} ; $t_{1/2} = 20$ min) was frequently produced at the Ernest Lawrence laboratory in Berkeley by blasting boron oxide with deuterons. Later, in the 1970, the Welch lab and Raichle and coworkers actively used the photosynthesis-based technique to produce ^{11}C -labeled glucose (27, 28). The manufacture of carbon-14 was thereafter vigorously pursued by Kamen and Ruben. They could have built it based on calculations, but despite expecting it to have a longer half-life, they had no idea what it would be (29). On Berkeley's 60-inch cyclotron, Kamen created an iron target and attacked it with 5700 Amp Hours of 7 to 8 MeV deuterons in 1940. By precipitating $CaCO_3$, Ruben examined the irradiated target and discovered persistent activity that may be attributed to carbon-14 (30). The estimated half-life of carbon-14 by

Kamen and Ruben was 4000 years, which was relatively close to the actual half-life, which was discovered many years later and is 5700 years (31).

- 4. The $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ Generator and Radiopharmaceuticals Labeled with $^{99\text{m}}\text{Tc}$:** Segre and Perrier made the discovery of the element technetium in Palermo, Italy, in 1937 (32). In order to examine the element's shorter-lived radionuclides, Segre went back to Berkeley and collaborated with Seaborg. This research resulted in the finding of technetium 99m ($t_{1/2}$ 6 h) (33). In the 1950s and 1960s, Powell Richards strongly promoted the use of technetium-99m as the ideal nuclear material for imaging molecular function in vivo due to its wide chemistry, intermediate photon half-life, photon energy of 140 keV, and lack of particle emissions (34, 35). Beck noted that in the 1960s, 150 keV was the appropriate detection energy for sodium iodide crystals (36). Iodine-132 rather than technetium 99m was the first generator system to be created (from tellurium-132)(54). The radioactive impurity in this tellurium-132, which was produced from fission products, was discovered by chance(37, 38). The tellurium-132 was subsequently shown to be followed by the impurity molybdenum-99 during the separation process, which was later used to create the Mo-99/Tc-99m generator (39).
- 5. Instrumentation for imaging development:** The invention of the rectilinear scanner, which during the 1950s and the beginning of the 1970s served as the primary instrument for nuclear imaging and automated the scanner's location, was the next major development. The time it took to photograph big organs was a major drawback of this technology. Hal Anger made a huge advancement in this area using several photomultiplier tubes and a collimated gamma camera to examine the whole of the target organ at once to increase the effectiveness of detection (40, 41.). In 1953, Brownell and Sweet developed a multidetector instrument using positron-emitting radionuclides to detect brain tumors (42, 43, 44).David Kuhl and Roy Edwards introduced the ideas of longitudinal and transaxial tomography and a nuclear medicine tomographic imaging apparatus in the 1960s (45). Transverse axial tomography was used by Godfrey Hounsfield to produce radiography, which he later used to create positron emission tomography (PET)(46).In 1975, Ter-Pogossian-filtered back projection, Phelps, and Hoffman were used to create a PET device (47, 48).The first camera that revolved around the patient wasn't invented until Keyes et al.1977 's study at the University of Michigan (49). Larsson introduced the cantilever system in the 1980s as a result of this (50).
- 6. Radionuclide Manufacturing:** After the cyclotron was built at Berkeley and Irene Curie and Frederic Joliet discovered how to create isotopes artificially, carbon-11 ($t_{1/2}$ -20 min), nitrogen-13 ($t_{1/2}$ -10 min), and fluorine-18 ($t_{1/2}$ 120 min) were produced and used as biological radiotracers. Kamen investigated how plants absorb carbon dioxide that had been tagged with carbon-11 in the 1930s (51).Furthermore, Cramer and Kistiakowsky studied metabolic pathways using lactic acid tagged with carbon-11 in the 1, 2, and 3 locations (52).Tobias et al. employed carbon-11 for the first time in people to explore how carbon monoxide behaved in people after being labeled with ^{11}C (53). Rueben et al's initial investigation using nitrogen-13 was aimed at investigating nitrogen fixing by non legume plants. Volker et al. studied the uptake of fluoride by bone and tooth enamel using fluorine-18 in the early 1940s. Nevertheless, despite these early developments, curiosity about these transient radionuclides decreased in the 1940s and 1950s (54). In order to measure the oxygen tension in malignant neoplasms, Powers and Ter-Pogossian created

oxygen-15 ($t_{1/2} = 2.0$ min) in the physics department of Washington University's cyclotron in the 1950s. This innovation spurred an increase in evaluating cerebral metabolic studies and repertoire using radioactive gases (55, 56).

7. **The Discoveries and Uses of FDG:** 2-Deoxy-2- ^{18}F Fluoro-D-glucose, often known as ^{18}F , Fig.2.shows that the hexokinase process is prevented by eliminating the hydroxyl in the 2-position.fluorine-18 atom replaces a hydroxyl group in the radiolabeled form of glucose known as FDG, sometimes known as just FDG. FDG was created specifically to track how much glucose is being used by the human brain. The hexokinase reaction is isolated when 2-deoxyglucose is used (57).Louis Sokoloff and Martin Reivich's 1975 science article proved to be a very useful resource in order to research glucose metabolism (58).




Figure 1: Shows that the hexokinase process is prevented by eliminating the hydroxyl in the 2-position.all carbons in the molecule of glucose are numbered, highlighted by the red arrow that Sokoloff and Reivich have assigned the carbon-14 designation to.

To see the ^{18}F FDG in a human, it was essential to fly the substance to Philadelphia, , the closest PET scanner at the time. It should come as no surprise that the logistics were difficult. Brookhaven developed the ^{18}F FDG, driven to the University of Pennsylvania for administration (59). Following this initial delivery, ^{18}F FDG's clinical application significantly increased. Preclinical research undertaken in the late 1970s and early 1980s found that ^{18}F FDG, despite initially being gain imaging, may also be effective for monitoring heart metabolism and tumor metabolism (60). Kurt Hamacher made a big development by using ^{18}F fluoride to synthesize FDG in 1986 (61) (Fig.3).




Figure 2: FDG synthesis

8. A brief history of Indian nuclear medicine: Considering the development of nuclear medicine in India historically, "Dr. Homi Jehangir Bhabha," known as the "Father of Indian Nuclear Program," must be mentioned. After India gained its independence, Pandit Jawaharlal Nehru, the nation's first prime minister, gave Dr. Homi Bhabha the responsibility of leading and coordinating the country's ambitious nuclear energy programme (in 1948). Atomic Energy Establishment Trombay (AEET) was constructed by Dr. Bhabha in 1954. a pioneering research reactor in Asia and India outside of the USSR and Russia, APSARA, reached criticality in 1956. In 1960, the site of AEET also saw the operationalization of the second reactor, CIRUS. This resulted in the domestic manufacture and availability of numerous radionuclides with medical applications (^{131}I , ^{32}P , and ^{51}Cr). Particularly, radioiodine (^{131}I) was becoming more and more relevant in clinical studies and practice. Since the early 1960s, the Bhabha Atomic Research Center, later known as the Isotope Division of AEET, has undertaken the enormous challenge of producing and commercially supplying radiopharmaceuticals to hospitals in India (62, 63). In 1956, with approval from the the late Pandit Jawahar Lal Nehru, an Indian Prime Minister, the multidisciplinary study group known as "Radiation Cell" was established within the purview of the Ministry of Defense with the goal of conducting biomedical research utilizing radioisotopes and applying radiation to medicine. India began Allied Sciences and Nuclear Medicine Institute (INMAS) received approval from Delhi University in 1963 to offer the first programme of its kind in the world (64). The early 1960s contributions from the BARC Isotope Division and later the BRIT, the Board of Isotope and Radiation Technology (after 1989) served as the fundamental hub for the development and organization of India's current nuclear medicine culture (64). At KEM Hospital in Mumbai, In 1960, Dr. R. S. Satosker carried out the initial thyroid uptake measuring investigation. Later, at RMC, uptake measurements were standardized (65). The slow rectilinear scanner was purchased by RMC in 1965, and the fast rectilinear scanner took its place in 1969 (66). RMC began offering diploma programmes in radiation medicine and medical radioisotope techniques, both of which are approved by Mumbai University, in 1973. In 1982, the Indian government's National Board of Examination recognised nuclear medicine as a broad field of study and granted RMC accreditation for its Diplomate of National Board training programme. At the Sanjay Gandhi Postgraduate Institute in Lucknow, the MD programme began for the first time in Asia and India in 1990 (67). The Society of Nuclear Medicine, India (SNMI) is the oldest and biggest professional association, with 1425 nuclear medicine specialists as life members. The inaugural Annual Conference of SNMI, which was founded in 1967, was held at RMC in Mumbai in 1968 (65). Since then, SNMI has been holding its Annual Conferences across the nation with the aim of fostering scholarly dialogue and increasing clinician awareness of the modality. RMC hosted the SNMI's first Conference in 1969 (68). There have been 233 operational gamma cameras (SPECT/SPECT-computed tomography [CT] systems) in India since 1969, when the first gamma camera was commissioned at RMC. A revolution in molecular imaging had begun in India with the first PET (2002), first medical cyclotron (2002), and first PET-CT (2004; all of which were performed in Mumbai) (69, 70).Table.1 Nuclear medical facilities in India, categorized [Table data is driven by (71)]:

Facility name	Quantity in numbers
Gamma cameras/SPECT	163
SPECT-CT	70
PET-CT	222
PET-MRI	3
High dose radionuclide therapy ward	92
Cyclotron	19

CT: Computed tomography, SPECT: Single-photon emission CT, PET: Positron emission tomography, MRI: Magnetic resonance imaging Gamma cameras/SPECT.

A PhD in therapeutic nuclear medicine was first made available in 2015 by the Delhi-based All India Institute of Medical Sciences. Nuclear medicine facilities of the nation have rapidly expanded as a result of the design and deployment of affordable generators (Having low specific activity and loaded ⁹⁹Mo) using locally developed solvent extraction (Methyl Ethyl Ketone) technology. There are 293 nuclear medicine departments nationwide, according to the facilities list released by the Atomic Energy Regulatory Board in July 2018. The remaining 86 percent are privately held companies, of which 14% are owned by the government (71).

III. DESIGN OF RADIOPHARMACEUTICALS

Radiopharmaceuticals consist of two components i.e a radionuclide for permitting external scan, and non radioactive element for acting as a carrier for conducting the radionuclide to the particular organs (72). Radioactive elements are highly energetic unstable nuclides because of excess energy i.e stabilized by emission of electromagnetic radiation (α , β and γ) during the decaying process of radioactive elements (73). For diagnostic applications, Gamma or X-rays are produced by the radioactive element, and their detection allows for the determination of the radiopharmaceutical's concentration. In contrast, the radioactive material can be applied therapeutically, where the ionizing radiation released by the radionuclide's decay is used to kill cells.

Nuclear medicine technologies such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are used to detect radiations released by radionuclides that are dispersed throughout the body or in a specific area of the body.

The image's contrast will be determined by the difference in radionuclide concentration between the target tissue and the surrounding tissue. When the target/background ratio is normally at its best, static imaging provides a snapshot of the radionuclide distribution at a specific time after the injection of the tracer.

The radiopharmaceutical is made up of a linker between a radionuclide for medical or diagnostic use and a vector molecule, as illustrated in figure.

The radionuclide emits radiation, and tissues or cells that express substances are the target of the vector molecule with a specific intent to perform diagnostic and therapeutic procedures. The vector molecule may be a small molecule, a peptide, protein and nanoparticle. For the diagnostic and therapeutic purpose, the vector should have high specificity and selectivity when it is conjugated with radionuclide. When a radionuclide is present in ionic form, such as when $[^{131}\text{I}]\text{I}$ is used to treat thyroid cancer or when $[^{89}\text{Sr}]\text{Sr}^{2+}$ is used to treat bone pain, the radionuclide may also serve as a vector molecule.




Figure 3: Radiopharmaceutical design

The linker, which is the third component, aids in creating a secure bond between the vector molecule and the radionuclide. Bifunctional chelators are required for radiopharmaceuticals based on radiometals because they guarantee both a stable complex with radiometal nuclei and a covalent link with the vector.

Based on the decaying property of the radionuclide, it is determined that the radiopharmaceutical will be used for diagnostic or therapeutic purposes.

- 1. Vector:** For the production of, radiopharmaceutical, vector is the main component as it is responsible for targeting the tissues for maintaining the higher concentration of radionuclide. As a result, therapeutic radiopharmaceuticals can selectively irradiate the target cells while still providing the picture contrast necessary for diagnostic imaging.

Small molecules, peptides and proteins and cells are used as vectors that are explained further. For intracellular targets, small molecules are used as vectors because of having specific characteristics such as membrane permeability and designing molecules within the cytoplasm and nucleus and can cross the blood brain barrier (BBB). Small molecules including Biochemicals Fatty acid, amino acids, nucleosides and xenobiotics are used as vectors.

Peptides are used as vectors because many peptides are present in tumor tissues as compared to normal tissue. Peptides contain less than 50 amino acids and diffusion is higher into the target tissues and long retention period in tumor cells. Peptides are synthesized easily and have favorable pharmacokinetic characteristics such as fast clearance from the blood pool and non-targeted tissues, and high concentration in the target tissue.

- 2. Radionuclide:** Radionuclides are unstable and contain excess energy because of heavy nuclei or imbalance in ratio of proton and neutron. The electromagnetic radiations (gamma rays) or particles (alpha and beta particles) are released due to excess energy present in radionuclide. These can be produced artificially or spontaneously via cyclotrons, particle accelerators, or radioactive decay of additional radionuclides.

IV. NUCLEAR MEDICINE TECHNIQUES

In nuclear medicine, the camera will construct a picture taken at the radiation's emission points. The image is observed on the monitor and the anomalies are checked.(74). Two examples of these modalities are Positron Emission Tomography (PET) and Single Photon Emission Computerized Tomography (SPECT).

- 1. Single Photon Emission Computerized Tomography (SPECT):** Single-photon emission computed tomography (SPECT) is the most frequently used technique in diagnosis. It generates a three-dimensional image of the distribution of a radioactive tracer throughout the body following its injection into the bloodstream and subsequent uptake by particular organs (75). Utilizing specialized nuclear medicine cameras allows for this. So, using SPECT, a clinician can evaluate the perfusion and functionality of particular tissues. SPECT relies on the spinning detectors' detection of single photons emitted during a radionuclide's decay in order to produce a 3D image of the distribution of the radionuclide in the body (76). For efficient imaging, energies between 100 and 200 keV are required. Technetium (^{99m}Tc , $T_{1/2} = 6$ hours) in its metastable form is the radioisotope that is most frequently used in SPECT scans. In the clinic, the ^{99m}Tc -complexes are frequently used to assess cardiovascular illnesses, renal excretion, identify tumor lesions, and CNS disorders (77).

Table 1: Radionuclides frequently used in SPECT imaging

S No.	Radio Nuclei	Half Life (h)	Type of Emission	Photon emission Energy (MeV)
1	123I	13.2	Electron capture	0.16
2	99mTc	6	Isomeric transition	0.14
3	111In	67.9	Electron capture	0.17/0.25
4	67Ga	78.3	Electron capture	0.09/0.19/0.30
5	201Tl	73.1	Electron capture	0.17

2. **PET:** PET detects two photons with a combined energy of 511 keV that are released in opposing directions upon the annihilation of positronium, which is produced when an electron and a positron from a neutron-deficient nuclei unite(78).

Table 2: Commonly used radionuclides for PET (79, 80, 81)

S No.	Radio Nuclei	Half Life	Mode of decay	Decay Product	Energy (MeV)
1	11C	20.4 min	β^+	11B	0.960
2	13N	10 min	β^+	13C	1.199
3	15O	2.0min	β^+	15N	1.732
4	18F	109.8 min	β^+ , Electron Capture	18O	0.634
5	64Cu	12.8h	β^+ , Electron Capture	64Ni 64Zn	0.653 0.329-1.675
6	68Ga	67.6 min	β^+ , Electron Capture	68 Zn	1.899 0.227-2.821
7	76Br	16 h	β^+ , Electron Capture	76Se	3.382 0.599
8	82Rb	1.3 min	β^+ ,	82 Kr	3.378

V. APPLICATIONS OF NUCLEAR MEDICINE

1. Clinical applications

- Renal and urinary tract disorders:** 1.The renogram acquired using DTPA (Diethylene triamine pentaacetic acid) or ^{99m}Tc can tagged with ^{123}I Hippuran be used to differentiate between urinary blockage and atonic dilatation; measurements of cortical transit and entire kidney, as well as responsiveness to furosemide, can also be obtained (82,83,84). 2.Detection and monitoring of vesicoureteric reflux utilizing a direct cystogram with ^{99m}Tc pertechnetate or an indirect cystogram with ^{99m}Tc DTPA, both of which result in substantially lower gonadal irradiation than a radiological cystogram (85,86,87). 3.When determining creatinine clearance is not necessary, the overall clearance must be evaluated. A ^{99m}Tc DTPA or chromium-51 edetic acid intravenous injection is given between two and four hours later, two to three blood samples could be used to precisely calculate glomerular filtration rate (^{51}Cr EDTA). The latter method is more precise, simpler to use, does not involve collecting urine, and is helpful for renal illnesses that affect both kidneys equally(88). 4. Renal function evaluation of a person: this information is typically available during the initial stages of a ^{99m}Tc DTPA, ^{123}I Hippuran Renogram, or ^{99m}Tc DMSA uptake. This is indicated in the study of uropathies and particular nephropathies, which may inflict unequal damage to the kidneys both before and after surgery (89,90). 5.Accurate topographical description of kidney location, kidney morphology, and parenchymal damage using ^{99m}Tc DMSA static images (acute and chronic pyelonephritis, trauma) (91, 92).

Table 3: Detectors used in kidney and urinary tract conditions (93)

Detectors	Physiology
Diethylene triamine penta-acetic acid	glomerular fraction alone
Technetium ^{99m}Tc -dimercaptosuccinic acid	the tubular cells' uptake
Edetic acid-chromium 51	Only glomerular filtration can remove; in vivo measures are not appropriate
Hippuran ^{123}I	80 percent removed via tubular secretion and 20 percent through glomerular filtering
Pertechnetate technetium 99111	bladder-filling and -voiding tracer

- Pulmonary diseases:** 1.To confirm or rule out the identification of local long illness when chest x-ray pictures are normal or ambiguous (Small lungs, bronchiectasis, aspiration pneumonia, hyperlucent lungs, foreign body). With a normal scan, the chance of obtaining bronchiectasis or a foreign body is rather low when choosing individuals who need to have more invasive procedures exams, for example

(bronchoscopy, bronchography).2. Before performing surgery to remove a lobe, to assess lung function (bronchiectasis, sequestration).3. prior to doing angiography, to identify intrapulmonary shunts and other vascular irregularities (a negative scintigraphy result could prevent angiography).4. to monitor severe disease, such as cystic fibrosis, bronchiectasis, viral pneumonia after effects.5. The detection of primary arterial disease and pulmonary embolism requires coupled perfusion and ventilation investigations 6. in order to assess mucociliary removal (94, 95, 96, 97, 98)

Table 4: Tracers used in pulmonary diseases (93)

Tracers	Physiology	Comments
Macroaggregates-technetium 99m or human albumin microspheres-technetium 99m	Regional perfusion	high-quality static graphics that are simple to create, affordable, and age-inclusive
Krypton gas 81m	Localized ventilation	Good cost and organizational requirements, static images of high quality when breathing normally with a mask, and low sensitivity for subsegmental abnormalities in infants younger than one year
Xenon gas 133	Localized ventilation	Demands participation from the patient (patients must be over 6 years old), produces static, subpar photographs after a single breath, and is moderately priced.
Millimicrospheres aerosols-technitium 99m	Localized ventilation	Still needs more work standardization

- Hepatosplenic disorders:** 1) Jaundice to rule out in the child biliary atresia; to evaluate the biliary tree's post-surgical patency; to evaluate the choledocal cysts' discharge; and to determine the existence of dilated ducts, for example, Caroli's sickness. 2. Detection and monitoring of liver lesions that take up space using other imaging methods (computed tomography, ultrasound). 3) To find anomalies of the spleen and congenital heart disease that are present at birth (asplenia, polysplenia). (4) To identify accessory spleens or splenic trauma (idiopathic thrombocytopenic purpura)(99).

Table 5: Tracers used in Hepatosplenic Disorders

Tracers	Physiology
Colloid-technetium 99m	liver and spleen's reticuloendothelial systems uptake
Damaged red blood cells-technetium 99m	spleen's selective uptake
Iminodiacetic acid (N substituted)-technetium 99m	parenchymal liver cells' early absorption and biliary channels' excretion of the substance into the duodenum

- Gastrointestinal tract disorders:** 1. Gastroesophageal reflux disease diagnosis and monitoring (including the syndrome of near-miss sudden newborn death, recurrent lung infections, and chronic vomiting)(100).2. Studying conditions including caustic stricture, peptic oesophagitis, achalasia, and impaired neurogenic peristalsis (101, 102). 3.Meckel's diverticulum containing stomach mucosa is diagnosed (103). 4. evaluation of the 24-hour stomach emptying (104).

Table 6 : Tracers used to diagnose digestive system issues:

Colloid-technetium 99m	Static image activity is influenced by osteoblast activity and blood flow
Krypton 81 in glucose	because to the tracer's incredibly brief life, it disappears quickly.
Pertechnetate-technetium 99m	the stomach mucosa actively absorbs

- Thyroid disorders:** 1. Aplasia, ectopia, and regularly occurring glands are defined.2. Analyzing nodules in the neck and their connections to thyroid tissues.3. (3) Identification of a foliated lesion as a potential hyperactive adenoma in hyperthyroidism (rare in children) (123). A trusted tracer for determining thyroid function is 131 Iodine. Due to the high radiation, youngsters should not use it (105).
- Heart diseases:** 1) Evaluation of the left to right heart shunt with the help of ^{99m}Tc pertechnetate.2.Using ^{99m}Tc macroaggregates, the right to left cardiac shunt is evaluated (MAA).3. Red blood cells that have been ^{99m}Tc-labeled or iTc pertechnetate (first pass) can be used to measure the function of the left ventricle (equilibrium).4. Right ventricular function can be evaluated with an ^{81m}Kr infusion or ^{99m}Tc pertechnetate (first pass) (106,107).

Table 7: Tracers used in Heart disorders

Tracers	Physiology
Krypton gas-181m	The moment it makes contact with air, this isotope will leave the solution. If the ^{81m}Kr is administered continuously intravenously, The isotope will first go into the right heart before continuing on to the pulmonary circulation. Considering that the isotope will easily cross the alveolar barrier and discharge, normally it won't get into the left heart or pulmonary veins. Good right ventricular structural delineation can be attained without any left heart superposition, allowing for the assessment of right ventricular contractility.
Macroaggregates-technetium 99m	Following an intravenous injection, the isotope will frequently become caught in the first capillary plexus and stop moving completely across the pulmonary capillary bed. The isotope can be found in the systemic circulation, such as the kidneys, if there is a right-to-left shunt.
Pertechnetate-technetium 99m	Right heart will transport this isotope to the lungs, followed by the left heart and the systemic circulation. The left heart phase isotope will travel to the systemic vascular system as well as to the lungs again when there is left to right shunt. The value of the shunt is quantifiable
Technetium 99m red blood cells	Since the isotope is connected to red blood cells during this time, it is able to take several photographs of the beating heart throughout time to assess ventricular function. Function changes are measurable (ejection fraction).

2. Diagnostic applications: The diagnosis of disease is more routinely performed using nuclear medicine. In this instance, the patient is administered a radioactive material, and then its dispersion in the body (7). Following the administration of a radiopharmaceutical, its biokinetics are observed, and the target organ or body system is functionally studied, or the lesion viability and the targeted biological process are characterized and evaluated (3). The tool being utilized determines the mode of observation: 1) Imaging technology: shows the temporal distribution of radioactivity that is visible at specific times or over a predetermined period of time. Displays of images can be 2D (static/dynamic whole-body images), 3D (tomograms), or 4D (dynamic/temporal tomograms). 2) Calculating tools: Externally, a probe system is utilized to examine in vivo body system and organ function (called radioassay). It is important to remember that radionuclides are administered in such dosages for research and diagnostics that there are no detectable biological side effects (3). To visualize the activities of many organs, including the kidney, lung, thyroid, and heart, as well as bone metabolism and blood circulation, radiopharmaceuticals are administered orally, intravenously, or by inhalation in the imaging modality (108). Although the applications of integrated diagnostic systems have expanded

to include cardiology, neurology, and the imaging of inflammatory diseases, they have demonstrated their clinical worth most prominently in the field of oncology (109).

- **Oncology:** Imaging is essential for the accurate staging of the disease and the assessment of therapy response in the early identification of cancer. Contrarily, "conventional" nuclear medical imaging (planar and SPECT) and PET can offer significant additional functional data, albeit with a reduced spatial resolution compared to radiological methods. CT and MRI provide significant anatomical information but do not provide meaningful functional information on the observed lesions. Furthermore, by accurately co-registering anatomical and functional data obtained through the use of hybrid SPECT/CT and PET/CT equipment, complementary information is obtained that, in the field of oncology, translates into greater sensitivity (better ability to localize lesions) and greater specificity (exclusion of false positives caused by the physiological accumulation of radio composed): approach makes it possible to accurately determine the functional significance of uncertain lesions (110).
- **Differentiated thyroid cancer:** The most frequent endocrine neoplasia, differentiated thyroid cancer (CDT), often has one favorable prognosis. The standard course of treatment entails a complete thyroidectomy and iodine-131 ablation of any remaining thyroid tissue. The thyroid gland values are measured as part of the CDT follow-up together with the neck's ultrasonography and, if necessary, Iodine-131 scintigraphy (WBS). Lack of anatomical and physiological references, as well as radioiodine accumulation in thyroid tissue remnants that can mimic metastasis, can make it challenging to interpret the WBS. By finding more lesions, enabling accurate localization of lesions, and excluding lesions in regions of normal radioiodine accumulation, using hybrid SPECT/CT imaging, radioiodine scintigraphy in CDTs improves both sensitivity and specificity (110,111).
- **Diagnostic application of nuclear medicine in urology:** Between 50% and 60% of kidney tumors have been reported to be detectable with ^{18}F -FDG PET/CT as a first diagnosis. It has not been demonstrated to significantly improve on traditional imaging techniques like CT and MRI for this purpose. Although dual-phase delayed imaging and after forced diuresis imaging were undertaken to lessen the impact of physiological urine activity, neither strategy outperformed the standard imaging protocol. After the main tumor was surgically removed, Additionally, it was found that the uptake of ^{18}F FDG and the amount of GLUT 1 expression were not correlated (112,113,114). Standard procedures and recommendations do not advocate the regular staging of kidney tumors with ^{18}F -FDG PET/CT. The main cause of this is that due to the intensive physiological urine activity, ^{18}F -FDG frequently gives false-negative results for the underlying tumor. Nevertheless, it has been argued in patients who are at risk, it may be helpful in demonstrating extrarenal metastatic illness (115, 116).
- **Myocardial imaging of perfusion test:** Traditional methods cannot differentiate between benign and malignant conditions in 14% of T1 kidney tumor surgeries (4 cm), while the pathology results of 20–30% of operated cases are benign. As a result, a SPECT agent may be helpful for preoperative characterisation of primary renal

masses even though no PET agent can be demonstrated to do so. Tc-99m Traditional gamma cameras employ MIBI, a non-specific tumor agent, for imaging. It is maintained in benign and cancerous tumours with increased metabolic rate in the mitochondria of the cell (117). Oncocytomas have higher Tc-99m MIBI absorption than other forms of RCC because they include more mitochondria (118). According to the findings of the limited research on this topic, nearly all of the patients who had a pathologically confirmed oncocytoma and underwent a Tc-99m MIBI SPECT/CT evaluation before surgery were positive for the radioactive substance. Patients showed no Tc-99m MIBI uptake, who were determined to have other RCC subtypes. Oncocytoma sensitivity was shown to range from 83 to 100% (119). When staging a high-risk condition in RCC patients with metastatic disease, 18F-FDG PET/CT is helpful for assessing treatment response. However, more research on common use is required. High sensitivity and specificity are provided by Tc^{99m} MIBI SPECT/CT for the malignant-benign distinction of ambiguous renal tumours. Testicular tumor staging, restaging, and follow-up are all aided by ¹⁸F-FDG PET/CT, while not being engaged in the metabolic characterisation of original scrotal masses, particularly when evaluating seminoma patients who have a persistent retroperitoneal lesion larger than 3 cm after treatment. Ga⁶⁸ PSMA PET/CT has good sensitivity in all stages of prostate cancer, Its use is expanding, particularly in individuals with biochemical recurrence (120).

- **Cardiology:** For measuring and evaluating the signs and symptoms of ischemic heart disease, the main method for functional cardiac imaging is radioactive myocardial perfusion scintigraphy (MPS). For examining IHD, a popular noninvasive nuclear image acquisition method is SPECT (single-photon emission tomography) of the heart. Currently, SPECT is suitable for detecting and controlling IHD in all its facets, consisting of diagnostic, risk assessment and classification, myocardial viability testing, and left ventricular function testing (121). More recently, individuals who may have coronary artery disease have been able to receive better diagnosis, risk assessment, and treatment planning thanks to hybrid images that integrate coronary angiography with computed tomography (CT) and SPECT functional imaging (122). The first radiopharmaceutical used extensively in clinical myocardial perfusion imaging was Tl-201 chloride (123). Two technetium-based agents, sestamibi and tetrofosmin, are presently utilised frequently. ¹²³I-Metaiodobenzylguanidine (MIBG) is a guanethidine derivative having characteristics similar to those of the heart's adrenergic system transmitter norepinephrine. The ratio of uptake in the mediastinum to the myocardium (heart) is used to semi-quantitatively measure sympathetic innervation of the myocardium (124). I-123 15- (p-Iodophenyl) The beta-methyl fatty acid analogue 3-R, S-Methylpentadecanoic Acid (BMIPP) 15- (p-iodophenyl) S-Methyl-3-R, 3-Pentadecanoic Acid (BMIPP), Since the drug is retained in the myocardium for a while, SPECT imaging with a conventional gamma camera is more advantageous (125). Stress-only imaging was advised in a recent information statement from the American Society of Nuclear Cardiology (ASNC) when utilized on carefully chosen individuals (126). Over the past few years, major cardiac societies including the American College of Cardiology and American Heart Association, along with other imaging associations, have taken proactive steps to reduce the usage of cardiac imaging. To guarantee that doctors are, in the majority of cases, performing the right test on the right patient at the right time, for nuclear cardiology, acceptable

use criteria have been created (127). This has brought about a number of quick advancements that have improved the hardware in nuclear cardiology scanners' photon sensitivity. Furthermore, software that uses innovative SPECT reconstruction techniques on established and specialized systems has retained or even enhanced SPECT image quality with reduced count statistics. To minimize radiation exposure while retaining diagnostic performance, MPI procedures should be improved. This development includes the use of radionuclides with shorter half-lives, like Tc-99m and PET tracers, stress-only imaging when practical, and weight-based dose.(124).

- **Thyroid disease:** The iodine intake by the thyroid gland is controlled by the sodium-iodide symporter (NIS), which was initially identified by Kaminsky et al. in 1993 (128). Through the use of thyroid scintigraphy and radioiodine uptake tests, the thyroid cells' ability to absorb iodine is still frequently utilized to assess thyroid function (129). Thyroid scintigraphy shows the location of thyroid tissue that is actively producing thyroid hormones in addition to the morphological knowledge obtained by ultrasonography (130). The assessment of technetium-99m absorption in the thyroid is given much attention. ^{99m}Tc uptake ranges from 0.5-2.0% in euthyroidism with typical iodine intake. Similar to iodine intake, this proportion falls in hypothyroidism, iodine pollution, and iodine insufficiency, while rising in Graves' illness. By comparing the number of counts in the regions of interest above the thyroid with the number of counts above the syringe carrying the ^{99m}Tc-pertechnetate before injection, this straightforward measurement is carried out as an addition to thyroid scintigraphy (131, 132, 133). Patients are photographed in a planar fashion when they are lying or sitting. ¹²³I, ¹³¹I, and ^{99m}Tc. Technetium-99m (^{99m}Tc), obtained from a molybdenum-technetium generator, is delivered intravenously in the form of pertechnetate. In a way similar to that of iodine isotopes, NIS delivers an analogue of iodine, ^{99m}Tc-pertechnetate, to thyroid cells. It is important to keep in mind that ^{99m}Tc absorption is not just restricted to thyroid tissue when interpreting scintigraphic pictures acquired with the radioactive substance. Thyroid imaging is another procedure that makes use of the iodine isotopes ¹²³I and ¹³¹I (130,132). The most often utilized radioactive isotope of iodine is ¹³¹I, sometimes known as radioiodine, with a half-life of 8.1 days; this nuclide emits both beta and gamma radiation. The energy of gamma rays is 364 keV and is employed in diagnostic procedures. Because of these drawbacks vs ^{99m}Tc and ¹²³I, ¹³¹I scintigraphy should only be used to track treatment in people with differentiated thyroid cancer (130,132). With PET and ¹⁸F-FDG, differentiated thyroid carcinoma can be detected. There are clinical situations in which a thyroid issue is unintentionally discovered during a PET/CT scan, despite the fact that it is not recommended to utilize PET to identify benign thyroid disease. For instance, a PET/CT scan using ¹⁸F-FDG can be used to distinguish between benign and malignant tumors when a single pulmonary nodule is present. Identifying the surgical indications in cases of a follicular neoplasm or an unclear biopsy is a difficulty that frequently arises in thyroid management. The positive predictive value (PPV) of an image of a metabolically active thyroid nodule ranged from 33 to 50% in different prospective investigations. Furthermore, the standardized uptake value (SUV) for glucose metabolism in the focal lesion did not improve PET's ability to diagnose (134,135). If a thyroid nodule is accidentally discovered to be metabolically active, a biopsy should be performed to rule for thyroid cancer. If there is diffuse ¹⁸F-FDG absorption, it is also advisable to prescribe TSH and thyroid antibodies (aTPO,

aTg) tests. Compared to conventional ^{131}I scintigraphy, the PET/CT with ^{124}I provides better accurate pictures with the benefit of having no influence on thyroid stunning (136). With this method, only differentiated thyroid carcinoma may be detected (137).

- **Pulmonary embolism:** If left untreated, PE has a significant fatality rate. The diagnosis cannot be made merely only on clinical findings or the results of straightforward tests like Blood chemistry, simple chest radiography, or ECG. Therefore, imaging studies are necessary to support or disprove a PE diagnosis. The following products are utilized for mapping regional ventilation: radiolabelled aerosols $^{99\text{m}}\text{Tc}$ -DTPA and $^{99\text{m}}\text{Tc}$ -labeled Technegas, inert gases ^{133}Xe and $^{81\text{m}}\text{Kr}$. Historically, the agent utilized for ventilation research was ^{133}Xe (138,139). By administering radioactive tracers to a vein in the arm, perfusion scintigraphy is carried out. The particles that are used in commerce are called MAA and are $^{99\text{m}}\text{Tc}$ -labeled (140). A dual or triple head gamma camera with a wide field of view is required for V/PSPECT in order to decrease acquisition time and the possibility of patient movement. Palmer et al. thoroughly investigated the correlations between SPECT imaging activities, acquisition periods, collimators, and matrices (141). V/PSPECT is highly advised since it enables accurate PE detection even when pneumonia and diseases like COPD are present. In COPD patients, Technegas is preferable over DTPA. When offered, $^{81\text{m}}\text{Kr}$ is beneficial. Reduce the radiation dose as much as possible without clinically significant image deterioration.. This means that before the perfusion scan, which uses 100-120 MBq for both the V/ PLANAR and V/PSPECT, the ventilation scan should use 30 MBq of $^{99\text{m}}\text{Tc}$ -aerosol. Only a perfusion scan is advised during pregnancy. Holistic interpretation should take the place of probability interpretation as it is no longer relevant. Mismatch in more than one subsegment is an essential PE criteria (141).

VI. FUTURE OF NUCLEAR MEDICINE

Applications of radioisotopes in nuclear medicine include both diagnostic and therapeutic procedures as we have already discussed in this chapter. Actually, the key factors that led to the development of nuclear medicine as a distinct medical field were the accomplishments in using radioiodine to treat thyroid issues, both benign and cancerous.

1. **Oncology:** Since 1990, the real number of cancer diagnoses has risen by 73%, despite the fact that In an age-standardized population, the incidence of invasive cancers has steadily decreased throughout the 1990s (142). This trend is caused by several factors, including an older population, higher incidence of cancer, and the detection of tumors through screening that would not have manifested as symptoms or resulted in death throughout the anticipated lifetime of a patient. From 469,000 in 1990 to 606,000 in 2020, 609,360 in 2022 number of cancer-related fatalities in the US has climbed more gradually (143,144).As a result, a lot more patients are coping with a cancer diagnosis. In light of this, it is all but likely that cancer imaging will continue to be a key area of nuclear medicine practise in the years to come.Currently, oncologic imaging investigations' interpretation is almost entirely a manual, subjective procedure, including the scrolling through many stacks of images by nuclear medicine specialists or radiologists with appropriate training to find and define anomalies. Given how quickly machine learning-based approaches to picture classification are developing, it is likely that this procedure

may soon be aided by or even replaced by computer systems (145). Because tumor and normal tissue generally contrast greatly, nuclear oncology imaging investigations appear to be especially well adapted for AI-based interpretation. This is already the case due to the use of tracers in therapeutic settings, such as PSMA ligand, ^{18}F -FDG, and somatostatin analogues. Presently, patient staging and restaging before and after therapeutic intervention predominate oncologic imaging. Nuclear imaging has been used in oncologic research to evaluate the pharmacokinetics of therapeutic drugs for many years. Two significant challenges were the inability to radiolabel medications in time for clinical use and the limited sensitivity of PET scanners, which only allowed imaging investigations a few hours after drug administration. Significant advancements made in recent years may help to get beyond both constraints. New total body systems exhibit previously unheard-of sensitivity and expand the time window for pharmaceutical research (146). Oncologic research will benefit greatly from the combination of radiolabeled antibodies and more sensitive PET devices (147). Initial efforts like pre-targeting and cutting-edge antibody labeling techniques show potential for minimizing radiation exposure and lowering the time between antibody injection and imaging (148). In oncologic molecular imaging, PET imaging of the dynamic TME following immune modulation therapy has emerged as the next frontier. It has been shown that using CD8-positive T cells and antibodies against programmed death ligand 1 labeled with ^{89}Zr for PET imaging improves the precision of predicting the results of immunotherapy and is superior to biopsy and immunohistochemistry (149). The targeting of immune cell markers using ^{89}Zr -labeled antibodies is the only restriction on their use. FAP inhibitors, which target the tumor stroma, can be used alone (150); they can be used in conjunction with cell-based therapies that target PSMA, such as CAR-T cells, that have reporter genes transfected into them, which can target both prostate cancer tumor cells and the PSMA-expressing tumor neovasculature, or they can be added to pretargeted strategies (like bispecific antibodies or bioorthogonal click chemistry) (151). Through the development of hybrid imaging methods like SPECT/CT, PET/CT, and PET/MRI, as well as the advent of PET, nuclear medicine technology has evolved during the past 20 years (152, 153). The development and commercialization of PSMA-targeted theranostics were spurred on by the success of peptide receptor radionuclide treatment. Major clinical guidelines for the detection of biochemical recurrence now include PSMA-directed PET imaging as a key component (154). The FDA just received a new medication application for ^{68}Ga -PSMA11, and approval is anticipated soon. The ^{18}F -labeled PSMA ligand registration studies are still ongoing.

- 2. Neurology:** In the years to come, it is anticipated that a number of current research applications in the field of molecular brain imaging will become common therapeutic tools. This shift encompasses both technological and radiotracer developments. Additionally, innovative and interesting research methodologies will develop. It is reasonable to suppose that brain PET tracers in the future would be available to imaging the majority of neurodegenerative diseases, if not all of them. This would be an example of effective research translation from the bench to the bedside. This progression began with the known b-amyloid PET tracers' acceptance some time ago and continued with the first authorized tau PET tracer (155). As the clinical use of molecular brain imaging significantly develops, the criteria and diagnostic methods now used for neurodegenerative illnesses are expected to be scrutinised. This alteration in perspective is primarily driven by the inability to offer disease-modifying therapies for any of these

conditions up to this point given the way they are currently diagnosed. It was recently proposed to begin with AD and replace the disease's current classification as a syndromal construct with a biologic definition that includes running diagnostic tests for neurodegeneration, tau, and amyloid (the so-called ATN concept) (156). Growing evidence indicates that the role of PET imaging in the context of treatment stratification and therapy monitoring will increase, which is consistent with the anticipated paradigm change on how to identify neurodegenerative illnesses. There is optimism that the most innovative disease-modifying treatment approach for neurodegeneration, aducanumab, a human monoclonal antibody, will be granted a license for clinical usage in anti-amyloid drugs for AD (157). Experts believe that in order to justify drug administration, a positive PET scan for amyloid demonstrating the actual existence of therapeutic target will be necessary because such medications will be highly expensive and may have important adverse effects. Based on the knowledge gained from drug testing trials conducted on individuals with a suspected AD clinical diagnosis, such an application seems reasonable. About 20% of these individuals had baseline amyloid PET results that were negative despite standard evaluation by experienced doctors (158). In terms of technical developments, in the years to come, there will surely be additional research addressing the critical question of the clinical use of the use of AI and hybrid PET/MRI in molecular brain imaging (despite the value proved in research). Many experts anticipate that once disease-modifying medicines are available, AD will be the first clinical application for hybrid PET/MRI. For example, there is optimism that AI will be able to distinguish between different illness subtypes, which will improve differential diagnosis and treatment choices. Both in terms of academic study and therapeutic application, the future of molecular brain imaging appears promising (159).

- 3. Cardiology:** Nuclear medicine has been utilized in cardiovascular applications to measure ischemic heart disease's myocardial perfusion, function, and viability, as well as to guide revascularization operations. True molecularly focused imaging has not yet made an impact on clinical cardiovascular care comparable to oncology or neurology, despite continual advancements in imaging technology. This discrepancy is best explained by the fact that targeted molecular imaging—which is most effective when combined with targeted molecular therapies—has not always been required in cardiology, where mechanical interventional techniques and widely applicable, generalizable pharmacological therapies have generally predominated. However, molecular imaging will be the key to the development of cardiovascular nuclear medicine. This will be closely related to the advancement of cardiovascular medicine in the future, when molecularly focused approaches will become increasingly important (160). One excellent example of how molecular imaging will become clinically relevant when targeted medicines define a particular need is the recent radionuclide imaging's success in detecting cardiac amyloidosis (161). Nuclear imaging makes it simple to see chemokine receptors like CXCR4, also known as CC-motif chemokine receptor 2, is a kind of chemokine receptor (CCR2) and profibrotic proteins like FAP. The heart is the focal point of the circulatory system, but it also has an impact on a number of other systems, including the immunological and neurohumoral systems, therefore systems-based, holistic methods will increasingly dictate cardiovascular therapy. A systemic, targeted solution should take into account all of the impacts on the intended area and surrounding tissues because cardiovascular disorders are closely linked to disease of other organs and tissues. As a whole-body method, radionuclide-based molecular imaging is ideally suited

to find such systemic networks. One current illustration is the connection between inflammation and the kidneys, the brain, the hematopoietic system, the arterial wall, and the heart (162). Another instance is the recent focus on cardio oncology, which focuses on assessing how tumors affect the body and tumor therapies on the circulatory system (163). Therefore, new, targeted imaging methods that are created to guide particular molecular therapies in cardiovascular target tissues as well as the concurrent condition of networking distant organs and tissues will influence the future of cardiovascular nuclear medicine.

- 4. Radiopharmaceutical chemistry:** In order to best select molecular targets for radiopharmaceutical development, biologists from all disease fields must work closely with doctors to determine and prioritize clinical needs and open questions. This will be accurate for the creation of PET imaging with fresh radiotracers and theranostics (in oncology, cardiology, neurology, infection, and other domains). The use of radiometals, most notably ^{64}Cu and ^{89}Zr , has likely had the greatest expansion in terms of fundamental, translational, and clinical studies over the past few decades, despite the emergence of novel techniques for labeling molecules with ^{11}C and ^{18}F . Despite the substantial advancements previously made in the ^{68}Ga field, this should be a focus in the upcoming years. Given the promising clinical outcomes with ^{225}Ac -PSMA, future advances may focus on the usage of α -emitters (164). It is also possible to employ a well-designed tracer to non-invasively check on the efficacy of therapeutic medications that are used after the drug target. One illustration of this is the use of human epidermal growth factor receptor 2 imaging for drugs that target tyrosine kinase and block human epidermal growth factor receptor 2 (165).

- 5. Instrumentation and Analysis:** From simple, single-channel, position-sensitive probes with rectilinear scanning to complex detectors with great energy, spatial, and time resolution, nuclear imaging detectors have advanced. Planar cameras have given way to tomographs that can produce high-quality 3- and 4-dimensional data as a result of advances in imaging technology. Nuclear imaging equipment was coupled with CT and then MRI to provide precisely matched anatomic information to enhance that information. Parallel developments in mathematics and computing for the reconstruction and analysis of PET and SPECT images accompanied these improvements in hardware. Iterative image reconstruction methods based on statistical and physical models have brought about a new era of image quality and are currently the industry standard for both PET and SPECT. The development of novel data analysis techniques that can quantify intricate molecular processes like enzymatic activity and receptor binding as well as sophisticated image analysis techniques like pharmacokinetic models has significantly improved our ability to measure regional tracer concentration, first for PET and more recently for SPECT. Faster, more compact, and more precise detectors are now possible thanks to developments in material science and electronics (166). The creation of molecular imaging biomarkers is now possible thanks to the advancement of imaging technology and image-generating algorithms, which has created a setting with a wealth of biological and clinical data (167). The aim of published criteria like PERCIST for Cancer and ^{18}F -FDG PET and of organizations specializing in quantitative imaging in the US and Europe has been to establish standards for quantitative molecular imaging (168).

6. **Artificial intelligence:** Among the many research and development fields that AI is actively transforming, nuclear medicine and molecular imaging are just two. Early in the 1990s, publications that demonstrate concepts in the realms of cardiac and brain imaging demonstrated the potential of AI and neural network-based technologies for image processing and pattern recognition (169,170,171,172). Total-body PET scanner data that we begin to gather regarding physiologic and pathologic pathways may potentially be advantageous for training AI-based reconstruction algorithms. Thus, these methods could produce total-body PET-like images obtained with contemporary scanners without ultralong axial field of view, AI might serve an important part in maximizing impact of technological investments in nuclear medicine clinical practise (the same would be true for ultrafast PET detectors). If true, the modest spatial and temporal resolution that has always been regarded as a drawback of PET and SPECT imaging would be resolved, and readily available scanners would soon be able to provide an unmatched sensitivity combined with great spatial and temporal resolution. AI is likewise influencing the analysis and interpretation of nuclear medicine pictures.

At the beginning of the 2000s, a number of doctors legitimately questioned whether PET/CT systems were clinically necessary (173). To increase access to clinical PET imaging, SPECT/PET systems were considered a possible tactic (174). Until recently, it was thought that imaging radiolabeled PSMA for prostate cancer inhibitors was not possible (175). There were also convincing arguments that creating novel imaging agents is typically too expensive to be profitable (176). Radioisotopes are frequently used in nuclear medicine to diagnose and treat human illnesses. However, the relative relevance of nuclear medicine's diagnostic and therapeutic applications has fluctuated throughout time. Internal medicine gave rise to nuclear medicine, which was initially used in clinical settings primarily for investigations of the pathophysiology of various diseases and the management of thyroid conditions (177,178). The American Board of Nuclear Medicine advocated for the removal of nuclear medicine as a separate medical specialty in the early 2010s because clinical nuclear medicine was so similar to radiology (179). The majority of people believed that the only financially viable task for nuclear medicine doctors was the precise ^{18}F -FDG PET/CT scan interpretation. On the basis of this premise, it seemed obvious that nuclear medicine should be added to the list of radiology's subspecialties.

In the interim, the FDA has approved a number of additional imaging products, consequently, it seems unlikely that nuclear medicine will be limited to reading ^{18}F -FDG PET/CT readouts in the future. The FDA's clearance of the theranostic pair ^{68}Ga -DOTATATE and ^{177}Lu -DOTATATE for use in imaging and treating neuroendocrine tumors, as well as the extremely encouraging outcomes from the use of radiolabeled PSMA ligands in imaging and treating prostate cancer, are even more significant. Therefore, it is very possible that therapeutic uses of radioisotopes will become increasingly important in future developments in clinical nuclear medicine. Simply said, nuclear radiology will retake nuclear medicine's place in the profession.

VII. CONCLUSION

An essential instrument for a comprehensive approach to medical radiation science is provided by nuclear medicine. It is established historically and in the evolution of contemporary best practice that nuclear medicine and both radiography and radiation

treatment complement one another. Clinical practitioners in all branches of the medical radiation sciences benefit from knowledge of the technical and clinical elements of integrated modalities. To enhance the skills of radiographers, radiation therapists, and other healthcare professionals working in the diagnostic imaging sector, this article offers a fundamental understanding of nuclear medicine. Since the area of nuclear medicine has been so inventive and quick to adapt to new scientific discoveries and clinical requirements, its development has been unexpected. Nuclear medicine will surely have a promising future if this success is sustained.

REFERENCES

- [1] Feinendegen LE. 1992. Nuclear medicine: a general overview and current trend. In 5th AOCNMB Jakarta-Bali, 25-30 October 1992.
- [2] Carlson S. A glance at the history of nuclear medicine. *Acta oncologica*. 1995 Jan 1;34(8):1095-102. DOI: 10.3109/02841869509127236
- [3] Tammat SR. 2006. Kimia Radiopharmaka. Workshop nasional preparasi dan aplikasi radiofarmaka. Pusat radioisotop dan radiofarmaka, BATAN.
- [4] International Atomic Energy Agency (IAEA). Operational guidance on hospital radiopharmacy : a safe and effective approach. Vienna: International Atomic Energy Agency, 2008. ISBN 978-92-0-106708-1. https://www-pub.iaea.org/MTCD/publications/PDF/Pub1342/Pub1342_web.pdf
- [5] Ziessman HA, O'Malley JP, Thrall JH. *Medicina nuclear*. Elsevier Brasil; 2014 Dec 10. <https://doi.org/10.1016/B978-0-323-08299-0.00001-8>
- [6] Badawi. RD.2001.Nuclear medicine. *Physics Education*.36(6):452. <https://www.researchgate.net/publication/231109484>.
- [7] L'annunziata MF. Radioactivity: introduction and history, from the quantum to quarks. Elsevier; 2016 May 13.
- [8] Imam SK. Molecular nuclear imaging: the radiopharmaceuticals. *Cancer biotherapy & radiopharmaceuticals*. 2005 Apr 1;20(2):163-72.. <https://doi.org/10.1089/cbr.2005.20.163.9>. Zanzonico P. Principles of nuclear medicine imaging: planar, SPECT, PET, multi-modality, and autoradiography systems. *Radiation research*. 2012 Apr;177(4):349-64.
- [9] Vallabhajosula S. Molecular imaging: radiopharmaceuticals for PET and SPECT. Springer Science & Business Media; 2009 Jul 13.
- [10] Sonia Marta Moriguchi, Kátia Hiromoto Koga, Paulo Henrique Alves Togni and Marcelo José dos Santos.2013.Clinical Applications of Nuclear Medicine.licensee InTech.
- [11] WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J. The future of nuclear medicine, molecular imaging, and theranostics. *Journal of Nuclear Medicine*. 2020 Dec 1;61(Supplement 2):263S-72S.
- [12] Gilmer PJ. Irène Joliot-Curie, a Nobel laureate in artificial radioactivity. In *Celebrating the 100th Anniversary of Madame Marie Skłodowska Curie's Nobel Prize in Chemistry 2011* Jan 1 (pp. 41-57). Brill Sense.
- [13] Anderson CJ, Ling X, Schlyer DJ, Cutler CS. A short history of nuclear medicine. In *Radiopharmaceutical Chemistry 2019* (pp. 11-26). Springer, Cham.
- [14] Orrman-Rossiter K. Places of 'Invention and Discovery' and the Nobel Prize in Physics. *Notes and Records*. 2021 Sep 20;75(3):439-60.
- [15] Niese S. George de Hevesy (1885–1966), founder of radioanalytical chemistry. *Czechoslovak Journal of Physics*. 2006 Dec;56(4):D3-11.
- [16] Christiansen IA, Hevesy G, Lomholt S. Radiochemical Method of Studying the Circulation of Bismuth in the Body. *C. R. Acad. Sci*. 1924; 178:1324.
- [17] Hevesy GV, Hofer E. Elimination of water from the human body. *Nature*. 1934 Dec;134(3397):879-.

- [18] Chiewitz O, Hevesy GD. Radioactive indicators in the study of phosphorus metabolism in rats. *Nature*. 1935 Nov;136(3445):754-5.
- [19] Abraham GE. The history of iodine in medicine Part II: Thyroid fixation and medical iodophobia. *Iodine Study # Optimox*. <http://www.optimox.com/iodine-study-16>. Accessed 8 July 2018.
- [20] Hertz S, Roberts A, Evans RD. Radioactive iodine as an indicator in the study of thyroid physiology. *Proceedings of the Society for Experimental Biology and Medicine*. 1938 May;38(4):510-3.
- [21] Livingood JJ, Seaborg GT. Radioactive isotopes of iodine. *Physical Review*. 1938 Nov 15;54(10):775.
- [22] Hamilton JG, Soley MH. Studies in iodine metabolism by the use of a new radioactive isotope of iodine. *American Journal of Physiology-Legacy Content*. 1939 Sep 30;127(3):557-72.
- [23] Keston AS, Ball RP, Frantz VK, Palmer WW. Storage of radioactive iodine in a metastasis from thyroid carcinoma. *Science*. 1942 Apr 3;95(2466):362-3.
- [24] Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. *Journal of the American Medical Association*. 1946 Dec 7;132(14):838-47.
- [25] Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. *European journal of nuclear medicine and molecular imaging*. 2008 Oct;35(10):1941-59.
- [26] Lifton JF, Welch MJ. Preparation of glucose labeled with 20-minute half-lived carbon-11. *Radiation Research*. 1971 Jan 1;45(1):35-40.
- [27] Raichle ME, Larson KB, Phelps ME, Grubb Jr RL, Welch MJ, Ter-Pogossian MM. In vivo measurement of brain glucose transport and metabolism employing glucose-11C. *American Journal of Physiology-Legacy Content*. 1975 Jun 1;228(6):1936-48.
- [28] Kamen MD, Kamen MD. *Radiant science, dark politics: a memoir of the nuclear age*. Univ of California Press; 1985.
- [29] Ruben S, Kamen MD. Long-lived radioactive carbon: C 14. *Physical Review*. 1941 Feb 15;59(4):349.
- [30] Kamen MD. Early history of carbon-14. *Science*. 1963;140(3567):584-90.
- [31] Perrier C, Segre E. Radioactive isotopes of element 43. *Nature*. 1937 Jul;140(3535):193-4.
- [32] Segrè E, Seaborg GT. Nuclear isomerism in element 43. *Physical Review*. 1938 Nov 1;54(9):772.
- [33] Richards P, Tucker WD, Srivastava SC. Technetium-99m: an historical perspective. *International Journal of Applied Radiation and Isotopes*. 1982;33(10):793-9.
- [34] Richards P. *Nuclide generators. Radioactive pharmaceuticals*. Oak Ridge: US Atomic Energy Commission; 1966.
- [35] Beck RN. A theoretical evaluation of brain scanning systems. *J. Nuclear Med.*. 1961 Oct 1;2.
- [36] Stang Jr LG, Tucker WD, Banks Jr HD, Doering RF, Mills TH. Production of iodine-132. Brookhaven National Lab.(BNL), Upton, NY (United States); 1954 Jan 1.
- [37] Stang Jr LG, Tucker WD, Doering RF, Weiss AJ, Greene MW, Banks Jr HO. Development of methods for the production of certain short-lived radioisotopes. *The International Journal of Applied Radiation and Isotopes*. 1957 Jan 1;2(3-4):252.
- [38] Tucker WD, Greene MW, Weiss AJ, Murrenhoff A. Methods of preparation of some carrier-free radioisotopes involving sorption on alumina. BNL 3746. In Annual Meeting, American Nuclear Society, Los Angeles, CA 1958 Jun.
- [39] Tapscott E. *Nuclear Medicine Pioneer, Hal O. Anger, 1920-2005*. *Journal of Nuclear Medicine Technology*. 2005 Dec 1;33(4):250.
- [40] Wagner HN. *A personal history of nuclear medicine*. London: Springer; 2006.
- [41] Brownell GL. *A history of positron imaging*. Physics Research Laboratory, Massachusetts General Hospital, MIT. 1999 Oct 15;1.
- [42] Nutt R. The history of positron emission tomography. *Molecular Imaging & Biology*. 2002 Jan 1;4(1):11-26.

- [43] Sweet WG. Localization of brain tumors with positron emitters. *Nucleonics*. 1953;11:40-5.
- [44] Kuhl DE, Edwards RQ. Reorganizing data from transverse section scans of the brain using digital processing. *Radiology*. 1968 Nov;91(5):975-83.
- [45] Hounsfield GN. Computerized transverse axial scanning (tomography): Part 1. Description of system. *The British journal of radiology*. 1973 Dec;46(552):1016-22.
- [46] Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. *Journal of nuclear medicine*. 1975 Mar 1;16(3):210-24.
- [47] Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomograph for nuclear imaging (PETT). *Radiology*. 1975 Jan;114(1):89-98.
- [48] Keyes JW, Orlandea N, Heetderks WJ, Leonard PF, Rogers WL. The Humongotron—a scintillation-camera transaxial tomograph. *Journal of Nuclear Medicine*. 1977 Apr 1;18(4):381-7.
- [49] Larsson SA. Gamma camera emission tomography. Development and properties of a multi-sectional emission computed tomography system. *Acta Radiol Suppl*. 1980;363:1-75.
- [50] Kamen MD. *Isotopic tracers in biology: an introduction to tracer methodology*. Elsevier; 2015 Dec 4.
- [51] Cramer RD, Kistiakowsky GB. The synthesis of radioactive lactic acid. *Journal of Biological Chemistry*. 1941 Feb 1;137(2):549-55.
- [52] Tobias CA, Lawrence JH, Roughton FJ, Root WS, Gregersen MI. The elimination of carbon monoxide from the human body with reference to the possible conversion of CO to CO₂. *American Journal of Physiology-Legacy Content*. 1945 Dec 1;145(2):253-63. <https://doi.org/10.1152/ajplegacy.1945.145.2.253>.
- [53] Volker JF, Hodge HC, Wilson HJ, Van Voorhis SN. The adsorption of fluorides by enamel, dentin, bone, and hydroxyapatite as shown by the radioactive isotope. *Journal of Biological Chemistry*. 1940;134:543-8.
- [54] Ter-Pogossian MM, Herscovitch P. Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism. In *Seminars in nuclear medicine* 1985 Oct 1 (Vol. 15, No. 4, pp. 377-394). WB Saunders.
- [55] Ter-Pogossian MM. The use of radioactive oxygen 15 in the determination of oxygen content in malignant neoplasms. In *Proc. of the 1st UNESCO Intern. Conf. Radioisotopes in Sci. Res.* 1958 (Vol. 3, pp. 625-636). Pergamon Press.
- [56] Sols A, Crane RK. Substrate specificity of brain hexokinase. *Journal of Biological Chemistry*. 1954 Oct 1;210(2):581-95.
- [57] Kennedy C, Des Rosiers MH, Jehle JW, Reivich M, Sharpe F, Sokoloff L. Mapping of functional neural pathways by autoradiographic survey of local metabolic rate with [¹⁴C] deoxyglucose. *Science*. 1975 Mar 7;187(4179):850-3.
- [58] Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Gallagher B, Hoffman E. Measurement of local cerebral glucose metabolism in man with/sup 18/F-2-fluoro-2-deoxy-D-glucose. *Acta Ophthalmol., Suppl.:(Denmark)*. 1977 Jan 1;56(64).
- [59] Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. *Journal of Nuclear Medicine*. 1980 Jul 1;21(7):670-5.
- [60] Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. *Journal of nuclear medicine*. 1986 Feb 1;27(2):235-8.
- [61] Samuel AM. Milestones in the growth of Radiation Medicine Center over past 25 years. IAEA Collection; 1989. p. 1-8. Available from: http://www.iaea.org/inis/collection/NCLCollectionStore/_Public/21/019/21019464.pdf. [Last retrieved on 2018 Oct 22].
- [62] Iya VK. The industrial production of tracers for use in nuclear medicine in India: current status and future prospects. *Radiation physics and chemistry*. 1986;28(2):245-9.
- [63] Nagaratnam A. Activities and achievements of INMAS. *Def Sci J* 1990;40:325-34

- [64] Samuel AM. Growth of nuclear medicine in India. *Def Sci J* 1990;40:335-46.
- [65] Rangarajan V, Purandare NC, Sharma AR, Shah S. PET/CT: Current status in India. *Indian Journal of Radiology and Imaging*. 2008 Oct;18(04):290-4.
- [66] Nayak UN. Human resource development at RMC. *RMC Golden Jubilee Memoirs*. 2013. p. 35-7
- [67] DaCosta H. Lest we forget. *RMC Golden Jubilee Memoirs*. BRNS Theme Meeting- Pioneering Nuclear Medicine in India; 2013. p. 17-27.
- [68] Lele RD. Nuclear medicine in India. *Def Sci J* 1990;40:347-50.
- [69] Kumaresan K. Low cost gamma camera? – The ECIL alternative. *Indian J Nucl Med* 1991;6:33-7.
- [70] Sharma AR. Nuclear medicine in India: A historical journey. *Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India*. 2018 Nov;33(Suppl 1):S5.
- [71] Cherry, S. R., Sorenson, J. A., Phelps, M. E. *Physics in Nuclear Medicine*. Elsevier Inc. ISBN978-1-4160-5198-5 2012.
- [72] <https://www.sciencedirect.com/topics/neuroscience/radiopharmaceuticals>.
- [73] World Health Organization (WHO). Diagnostic imaging. *Nuclear Medicine*. https://www.who.int/diagnostic_imaging/imaging_modalities/dim_nuclearmed/en/.
- [74] World Nuclear Association (WNA). Radionuclides in medicine. (Updated November 2018). <http://www.world-nuclear.org/information-library/non-power-nuclear-applications/radionuclides-research/radionuclides-in-medicine.aspx>.
- [75] Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, Kuwert T, la Fougère C, Mariani G, Massalha S, Paez D, Giammarile F. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. *Eur J Nucl Med Mol Imaging*. 2019 Sep;46(10):1990-2012. [PMC free article] [PubMed]
- [76] Hutton BF: The origins of SPECT and SPECT/CT. *Eur J Nucl Med Mol Imaging* 41:S3-16, 2014.
- [77] Adak S, Bhalla R, Vijaya Raj KK: Radiotracers for SPECT imaging: Current scenario and future prospects. *Radiochim Acta* 100:95-107, 2012
- [78] Pimlott SL, Sutherland A. Molecular tracers for the PET and SPECT imaging of disease. *Chemical Society Reviews*. 2011;40(1):149-62.
- [79] Conti M, Eriksson L: Physics of pure and non-pure positron emitters for PET: A review and a discussion. *EJNMMI Phys* 3:1-17, 2016
- [80] Müller C, Zhernosekov K, Köster U, et al: A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α - and bradionuclide therapy: An in vivo proof-of-concept study with a new receptor-targeted folate derivative. *J Nucl Med* 53:1951-1959, 2012
- [81] Mitterhauser M, Wadsak W: Imaging biomarkers or biomarker imaging? *Pharmaceuticals* 7:765-778, 2014
- [82] Piepsz A, Ham HR, Erbsmann F, Hall M, Diffey BL, Goggin MJ, Hall FM, Miller JA, Lumbroso J, Di Paola R, Bazin JP. A co-operative study on the clinical value of dynamic renal scanning with deconvolution analysis. *The British Journal of Radiology*. 1982 Jun;55(654):419-33.
- [83] O'Reilly PH. Diuresis renography 8 years later: an update. *The Journal of urology*. 1986 Nov;136(5):993-9.
- [84] Britton K, Nimmon CC, Whitfield HN, Hendry WF, Wickham JE. Obstructive nephropathy: successful evaluation with radionuclides. *The Lancet*. 1979 Apr 28;313(8122):905-7.
- [85] Conway JJ, Belman AB, King LR. Direct and indirect radionuclide cystography. In *Seminars in nuclear medicine* 1974 Apr 1 (Vol. 4, No. 2, pp. 197-211). WB Saunders.
- [86] Willi UV, Treves ST. Radionuclide voiding cystography. In: Treves SD, ed. *Paediatric nuclear medicine*. New York: Springer Verlag, 1985:105-20.
- [87] Pollet JE, Sharp PF, Smith FW. Radionuclide imaging for vesico-renal reflux using intravenous ^{99m}Tc -DTPA. *Pediatric Radiology*. 1979 Sep;8(3):165-7.

- [88] Chantler C, Garnett ES, Parsons V, Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. *Clinical science*. 1969 Aug 1;37(1):169-80.
- [89] Piepsz A, Denis R, Ham HR, Dobbeleir A, Schulman C, Erbsmann F. A simple method for measuring separate glomerular filtration rate using a single injection of 99m TcDPTA and the scintillation camera. *J Pediatr* 1978;93:769-74.
- [90] Tauxe WN, Dubousky EV. Nuclear medicine in clinical urology and nephrology.
- [91] Ciofetta G, Gordon I, Piepsz A. Clinical applications of nuclear medicine. *Archives of disease in childhood*. 1988 Mar;63(3):321.
- [92] Goldraich NP, Borratt TM. Vesico ureteric reflux and scanning. In: Holliday MA, Bowatt TM, Vernier RL, eds. *Pediatric nephrology*. Baltimore: Williams & Wilkins, 1987:647-66.
- [93] G CIOFETTA, I GORDON, AND A PIEPSZ. Clinical applications of nuclear medicine. *Archives of Disease in Childhood*, 1988, 63, 321-328.
- [94] Godfrey S, McKenzie SA. The place of radioisotopic lung function studies in paediatrics. *Arch Dis Child* 1978;52:859-64. 5
- [95] Ciofetta G, Silverman M, Hughes JMB. Quantitative approach to the study of regional lung function in children using krypton81m. *Br J Radiol* 1980;53:950-9. ""
- [96] Gordon I, Helms P, Fazio F. Clinical application of radionuclide lung scanning in infants and children. *Br J Radiol* 1981;54: 576-85.
- [97] Treves ST. *Pediatric nuclear medicine*. New York: Springer Verlag, 1985.
- [98] Vandevivere J, Spehl M, Dab J, et al. Bronchiectasis in childhood. Comparison between chest roentgenograms, bronchography and lung scintigraphy. *Pediatr Radiol* 1980;9: 193-8.
- [99] Siddiqui AR. *Nuclear imaging in pediatrics*. Chicago: Year Book Medical Publishers, 1985.
- [100] Heyman S. Esophageal scintigraphy (milk scans) in infants and children with gastr,esophageal reflux. *Radiology* 1984;144: 891-3.
- [101] Ham HR, Piepsz A, Gorges B, et al. Quantitation of esophageal transit by means of 81m Krypton. *Eur J Nucl Med* 1984;9:362-5.
- [102] Guillet J, Wynchank S, Basse-Cathalinat CE, Blanquet P. Pediatric esophageal scintigraphy: results of 200 studies. *Clin Nucl Med* 1983;8:427-33.
- [103] Sfakianakis GN, Conway JJ. Detection of ectopic gastric mucosa in Meckel's diverticulum and in other aberrations by scintigraphy. *Pathophysiology and 10-year clinical experience*. *J Nucl Med* 1981;22:647-54
- [104] Di Lorenzo C, Piepsz A, Ham HR, Cadranel S. Gastric emptying with gastro-oesophageal reflux. *Arch Dis Child* 1987;62:449-53.
- [105] Beckhuis H, Piers DA. Radiation risk of thyroid scintigraphy in newborns. *Eur J Nucl Med* 1983;8:348-50.
- [106] Ham HR, Dobbeleir A, Viart P, et al. Radionuclide quantitation of left-to-right cardiac shunts using deconvolution analysis: concise communication. *J Nucl Med* 1981;22:688-92.
- [107] Piepsz A, Ham HR, Millet E, Dab I. Determination of right ventricular ejection fraction in children with cystic fibrosis. *Pediatric Pulmonology* 1987;3:24-8.
- [108] World Health Organization (WHO). Diagnostic imaging. Nuclear Medicine. https://www.who.int/diagnostic_imaging/imaging_modalities/dim_nuclearmed/en/.
- [109] Maurer AH. Combined imaging modalities: PET/CT and SPECT/ CT. *Health Phys* 2008;95(5):571—6
- [110] Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. *Clin Radiol* 2008;63(3):241—51. R
- [111] Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzch man M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2004;31(10):1435—42.
- [112] Kamel EM, Jichlinski P, Prior JO et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. *J Nucl Med* 2006; 47:1803-1807.
- [113] Ozülker T, Ozülker F, Ozbek E et al. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/ computed tomography in the evaluation of indeterminate renal masses. *Nucl Med Commun* 2011;32:265-272.

- [114] Ferda J, Ferdova E, Hora M et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. *Anticancer Res* 2013;33:2665-2672.
- [115] Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. *J Urol* 2004;171:1806-1809.
- [116] Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma. *Cancer Imaging* 2012;12:464-474.
- [117] Moretti JL, Hauet N, Caglar M, et al. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. *Eur J Nucl Med* 2005;32:836-842
- [118] Gormley TS1, Van Every MJ, Moreno AJ. Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging. *Urology* 1996;48:33-39.
- [119] Reynolds MA, Porter KK. Characterizing indeterminate renal masses with molecular imaging: the role of 99mTc-MIBI SPECT/CT. *Curr Urol Rep* 2017;18:86
- [120] Mine Araz , Yüksel Ürün . Nuclear Medicine in Urological Tumors. *Bull Urooncol* 2019;18:80-88. DOI: 10.4274/uob.galenos.2018.1132
- [121] Health Quality Ontario. Single photon emission computed tomography for the diagnosis of coronary artery disease: an evidence-based analysis. *Ont Health Technol Assess Ser* 2010; 10:1-64
- [122] 2006 image of the year: focus on cardiac SPECT/CT. *J Nucl Med* 2006;47:14N-5N.
- [123] Lebowitz E, Greene MW, Fairchild R, Bradley-Moore PR, Atkins HL, Ansari AN, et al. Thallium-201 for medical use. I. *J Nucl Med* 1975;16:151-5
- [124] Kyoung Sook Won and Bong-Il Song. Recent Trends in Nuclear Cardiology Practice. *Chonnam Med J* 2013;49:55-64.
- [125] Shi CQ, Young LH, Daher E, DiBella EV, Liu YH, Heller EN, et al. Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. *J Nucl Med* 2002;43:421-31.
- [126] Cerqueira MD, Allman KC, Ficaro EP, Hansen CL, Nichols KJ, Thompson RC, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. *J Nucl Cardiol* 2010; 17:709-18.
- [127] Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al; American College of Cardiology Foundation Appropriate Use Criteria Task Force; American Society of Nuclear Cardiology; American College of Radiology; American Heart Association; American Society of Echocardiology; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; Society of Nuclear Medicine. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American college of cardiology foundation appropriate use criteria task force, the American society of nuclear cardiology, the American college of radiology, the American heart association, the American society of echocardiography, the society of cardiovascular computed tomography, the society for cardiovascular magnetic resonance, and the society of nuclear medicine. *J Am Coll Cardiol* 2009;53:2201-29.
- [128] Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. The Na⁺/I symporter of the thyroid gland. *Soc Gen Physiol Ser* 1993; 48: 251–262.
- [129] Chung JK. Sodium iodide symporter: its role in nuclear medicine. *J Nucl Med* 2002; 43: 1188–1200.
- [130] Pfannenstiel P, Hotze LA, Saller B. Schilddrusenerkrankungen: Diagnose und Therapie. *Berliner Medizinische Verlagsanstalt* 1997; 86–9.
- [131] Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Deutsche Gesellschaft für Nuklearmedizin; Deutsche Gesellschaft für Medizinische Physik. Procedure guideline for thyroid scintigraphy (version 3). *Nuklearmedizin* 2007; 46: 203–205.
- [132] Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. *Eur J Nucl Med* 2002; 29 (Suppl 2): S425–S38.

- [133] Kresnik E, Gallowitsch HJ, Mikosch P et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. *Surgery* 2003; 133: 294–299.
- [134] Smith RB, Robinson RA, Hoffman HT, Graham MM. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid. *Otolaryngol Head Neck Surg* 2008; 138: 101–106.
- [135] Sebastianes FM, Cerci JJ, Zanoni PH et al. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. *J Clin Endocrinol Metab* 2007; 92: 4485–4488
- [136] Capocchetti F, Criscuoli B, Rossi G, Ferretti F, Manni C, Brianzoni E. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. *Q J Nucl Med Mol Imaging* 2009; 53: 536–545
- [137] Rafał Czepczyński. Nuclear medicine in the diagnosis of benign thyroid diseases. *Nuclear Medicine Review* 2012, 15, 2: 113–119 10.5603/NMR.2012.0008.
- [138] Dollery CT, Gillam PM. The distribution of blood and gas within the lungs measured by scanning after administration of 133Xe. *Thorax* 1963;18:316–25. doi:10.1136/thx.18.4.316.
- [139] Knipping HW, Bolt W, Venrath H, Valentin H, Ludes H, Endler P. A new method of heart and lung function testing, the regional functional analysis in the lung and heart clinic by the radioactive noble gas xenon 133 (isotope thoracography). *Dtsch Med Wochenschr* 1955;80:1146–7.
- [140] Heck LL, Duley JW Jr. Statistical considerations in lung imaging with 99mTc albumin particles. *Radiology* 1974;113:675–9.
- [141] Palmer J, Bitzen U, Jonson B, Bajc M. Comprehensive ventilation/perfusion SPECT. *J Nucl Med* 2001;42:1288–94.
- [142] M. Bajc & J. B. Neilly & M. Miniati & C. Schuemichen & M. Meignan & B. Jonson. EANM guidelines for ventilation/perfusion scintigraphy Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. *Eur J Nucl Med Mol Imaging* (2009) 36:1356–1370.
- [143] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70:7–30.
- [144] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. *CA CANCER J CLIN* 2022;72:7–33.
- [145] Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. *Nat Med*. 2019;25:954–961.
- [146] Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. *J Nucl Med*. 2019;60:299–303.
- [147] Lohrmann C, O'Reilly EM, O'Donoghue JA, et al. Retooling a blood-based biomarker: phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer. *Clin Cancer Res*. 2019;25:7014–7023
- [148] Houghton JL, Zeglis BM, Abdel-Atti D, Sawada R, Scholz WW, Lewis JS. Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses. *J Nucl Med*. 2016;57:453–459
- [149] van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, et al. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. *Theranostics*. 2020;10:1708–1718
- [150] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. *J Nucl Med*. 2019;60:801–805
- [151] Martinez O, Sosabowski J, Maher J, Papa S. New developments in imaging cell[1]based therapy. *J Nucl Med*. 2019;60:730–735
- [152] Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. *J Nucl Med*. 2019;60(suppl 2):13S–19S.
- [153] Herrmann K, Schwaiger M, Lewis JS, et al. Radiotheranostics: a roadmap for future development. *Lancet Oncol*. 2020;21:e146–e156.

- [154] Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on pros[1]tate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. *Eur Urol*. 2017;71:630–642.
- [155] FDA approves Tauvid as first tau protein tracer tool for Alzheimer’s diagnosis. *Alzheimer’s News Today website*. <https://alzheimersnewstoday.com/2020/06/01/fda-approves-tauvid-first-tau-protein-tracer-agent-alzheimers-diagnosis>. Published June 1, 2020. Accessed August 4, 2020
- [156] Jack CR, Bennett D, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. *Alzheimers Dement*. 2018;14:535– 562.
- [157] FDA filing of Alzheimer’s therapy aducanumab delayed to late 2020, Biogen says. *Alzheimer’s News Today website*. <https://alzheimersnewstoday.com/2020/04/27/fda-filing-of-alzheimers-therapy-aducanumb-delayed-to-late-2020>. Published April 27, 2020. Accessed August 4, 2020
- [158] Barthel H, Seibyl J, Sabri O. The role of positron emission tomography imaging in understanding Alzheimer’s disease. *Expert Rev Neurother*. 2015;15:395–406
- [159] Werner RA, Thackeray JT, Diekmann J, Weiberg D, Bauersachs J, Bengel FM. The changing face of nuclear cardiology: guiding cardiovascular care toward molecular medicine. *J Nucl Med*. 2020;61:951–961.
- [160] Masri A, Bukhari S, Eisele YS, Soman P. Molecular imaging of cardiac amy[1]loidosis. *J Nucl Med*. 2020;61:965–97
- [161] Thackeray JT. Imaging the molecular footprints of the heart-brain axis in car[1]diovascular disease. *J Nucl Med*. 2019;60
- [162] Dreyfuss AD, Bravo P, Koumenis C, Ky B. Precision cardio-oncology. *J Nucl Med*. 2019;60:443–450.
- [163] Kratochwil C, Bruchertseifer F, Giesel FL, et al. ²²⁵Ac-PSMA-617 for PSMA[1]targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. *J Nucl Med*. 2016;57:1941–1944.
- [164] Sanchez-Vega F, Hechtman JF, Castel P, et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. *Cancer Discov*. 2019;9:199–209.
- [165] 165. Surti S, Viswanath V, Daube-Witherspoon ME, Conti M, Casey ME, Karp JS. Benefit of improved performance with state-of-the art digital PET/CT for lesion detection in oncology. *J Nucl Med*. March 20, 2020 [Epub ahead of print].
- [166] Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. *J Nucl Med*. 2014;55:525–528.
- [167] Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009;50(suppl 1):122S–150S.
- [168] Scott R. Artificial intelligence: its use in medical diagnosis. *J Nucl Med*. 1993;34:510– 514
- [169] Links JM, Devous MD Sr. Detection and comparison of patterns in images. *J Nucl Med*. 1994;35:16–17.
- [170] Fujita H, Katafuchi T, Uehara T, Nishimura T. Application of artificial neural network to computer-aided diagnosis of coronary artery disease in myocardial SPECT bull’s-eye images. *J Nucl Med*. 1992;33:272–276
- [171] Kippenhan JS, Barker WW, Pascal S, Nagel J, Duara R. Evaluation of a neural[1]network classifier for PET scans of normal and Alzheimer’s disease subjects. *J Nucl Med*. 1992;33:1459–1467
- [172] Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: panacea, redundancy, or something in between? *J Nucl Med*. 2004;45(suppl 1):15S–24S
- [173] Weber W, Young C, Abdel-Dayem HM, et al. Assessment of pulmonary lesions with ¹⁸F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. *J Nucl Med*. 1999;40:574–578.

- [174] Rowe SP, Gorin MA, Pomper MG. Imaging of prostate-specific membrane an[1]tigen with small-molecule PET radiotracers: from the bench to advanced clinical applications. *Annu Rev Med.* 2019;70:461–477.
- [175] Nunn AD. The cost of developing imaging agents for routine clinical use. *Invest Radiol.* 2006;41:206–212.
- [176] Seidlin SM, Marinelle LD, Oshri E. Radioactive iodine therapy; effect on func[1]tioning metastases of adenocarcinoma of the thyroid. *J Am Med Assoc.* 1946; 132:838–847
- [177] Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves' disease. *J Clin Invest.* 1942; 21:25–29.
- [178] Segall GM. Looking to the future: the ABNM in the next 10 years. *J Nucl Med.* 2016;57(2):12N.
- [179] Czernin J. Roundtable on the future of nuclear medicine training [reply]. *J Nucl Med.* 2015;56:1969–1970